Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherAssets,cash,totalCurrentLiabilities,shortLongTermDebt,propertyPlantEquipment,totalCurrentAssets,longTermDebt,accountsPayable,netReceivables,changeToLiabilities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,changeToNetincome,totalCashflowsFromInvestingActivities,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,currency,priceHint,shortName,exchange,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,exchangeDataDelayedBy,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,dividendDate,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,marketState,postMarketChangePercent,postMarketTime,postMarketPrice,postMarketChange,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,market,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jun 29, 2021) 4","Short Ratio (Jun 29, 2021) 4","Short % of Float (Jun 29, 2021) 4","Short % of Shares Outstanding (Jun 29, 2021) 4","Shares Short (prior month May 27, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,fax,industry,address2
t0,GOVX,20575245.0,6327700,,,-1562778,,-1562778,1071710,-492366,-1564076,-1564076,,-755,,,,0,110417,1674493,602783,1298,,-1562778,-1562778,67937289.0,464106.0,20575245.0,21115446.0,6315.0,84363.0,-47368359.0,11010.0,20842782.0,451949.0,182844.0,143224.0,20961212.0,12157.0,232482.0,,-357878.0,-3063.0,12580013.0,35659.0,12583076.0,10958986.0,-1621027.0,4517.0,182663.0,76790.0,,,20509263.0,en-US,US,EQUITY,True,Delayed Quote,5.64,1630526402,-0.4500003,6.2215,6.26,5.545,1016838,0.6024275,0.11958686,35688228,-3.6623378,1.7311234,15,America/New_York,EDT,-14400000,False,False,USD,2,"GeoVax Labs, Inc.",NCM,-1.26,-4.4761906,3.258,4.635857,1.0041428,0.21660347,5.0375724,0,finmb_12056751,NasdaqCM,"GeoVax Labs, Inc.",USD,2564462,1601357,3.08,1.203125,2.56 - 8.71,-3.0700002,-0.35246843,2.56,8.71,1600992000,1620331200,1620331200,1620331200,-1.477,-1.54,PREPRE,1.773048,1630540756,5.74,0.099999905,-7.389167,5.545 - 6.26,6.09,0.0,0.0,13,9,us_market,1.78,,,8.71,2.56,4.64,5.04,2.56M,1.6M,6.33M,,6.07M,8.31%,6.27%,181.61k,0.65,3.01%,2.87%,251.5k,,,,,,0.00%,"Sep 24, 2020",,1:20,"Sep 24, 2020","Dec 30, 2020","Mar 30, 2021",0.00%,-310.78%,-21.56%,-41.79%,1.22M,0.46,-84.60%,-620.8k,-3.76M,-3.93M,-1.48,,20.84M,3.3,195k,0.94,46.38,3.26,-4.01M,-4.25M,Value,30080,Healthcare,7,"GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against coronavirus (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; the HIV Vaccines Trial Network; Centers for Disease Control and Prevention; U.S. Department of Defense; U.S. Army Research Institute of Infectious Disease; U.S. Naval Research Laboratory; Emory University; University of Pittsburgh; Georgia State University Research Foundation; University of Texas Medical Branch; the Institute of Human Virology at the University of Maryland; the Scripps Research Institute; the Burnet Institute; American Gene Technologies International, Inc.; Viamune, Inc.; Geneva Foundation; the University of California; and Leidos, Inc. GeoVax Labs, Inc. was incorporated in 2001 and is based in Smyrna, Georgia.",Smyrna,678 384 7220,GA,1609372800,United States,http://www.geovax.com,86400,1900 Lake Park Drive,678 384 7281,Biotechnology,Suite 380
t-1,GOVX,9492757.0,6327700,,,-1336522,,-1336522,831364,-505725,-1337089,-1337089,,-802,,,,0,251621,1588710,757346,567,,-1336522,-1336522,55294504.0,825047.0,9492757.0,10393899.0,3834.0,120022.0,-45805581.0,11010.0,9883796.0,810309.0,183326.0,147741.0,10235148.0,14738.0,267702.0,182663.0,-114080.0,-3026.0,-526.0,-231161.0,2500.0,-1696798.0,-1541951.0,16673.0,-41509.0,40463.0,-154321.0,-154321.0,9424839.0,en-US,US,EQUITY,True,Delayed Quote,5.64,1630526402,-0.4500003,6.2215,6.26,5.545,1016838,0.6024275,0.11958686,35688228,-3.6623378,1.7311234,15,America/New_York,EDT,-14400000,False,False,USD,2,"GeoVax Labs, Inc.",NCM,-1.26,-4.4761906,3.258,4.635857,1.0041428,0.21660347,5.0375724,0,finmb_12056751,NasdaqCM,"GeoVax Labs, Inc.",USD,2564462,1601357,3.08,1.203125,2.56 - 8.71,-3.0700002,-0.35246843,2.56,8.71,1600992000,1620331200,1620331200,1620331200,-1.477,-1.54,PREPRE,1.773048,1630540756,5.74,0.099999905,-7.389167,5.545 - 6.26,6.09,0.0,0.0,13,9,us_market,1.78,,,8.71,2.56,4.64,5.04,2.56M,1.6M,6.33M,,6.07M,8.31%,6.27%,181.61k,0.65,3.01%,2.87%,251.5k,,,,,,0.00%,"Sep 24, 2020",,1:20,"Sep 24, 2020","Dec 30, 2020","Mar 30, 2021",0.00%,-310.78%,-21.56%,-41.79%,1.22M,0.46,-84.60%,-620.8k,-3.76M,-3.93M,-1.48,,20.84M,3.3,195k,0.94,46.38,3.26,-4.01M,-4.25M,Value,30080,Healthcare,7,"GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against coronavirus (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; the HIV Vaccines Trial Network; Centers for Disease Control and Prevention; U.S. Department of Defense; U.S. Army Research Institute of Infectious Disease; U.S. Naval Research Laboratory; Emory University; University of Pittsburgh; Georgia State University Research Foundation; University of Texas Medical Branch; the Institute of Human Virology at the University of Maryland; the Scripps Research Institute; the Burnet Institute; American Gene Technologies International, Inc.; Viamune, Inc.; Geneva Foundation; the University of California; and Leidos, Inc. GeoVax Labs, Inc. was incorporated in 2001 and is based in Smyrna, Georgia.",Smyrna,678 384 7220,GA,1609372800,United States,http://www.geovax.com,86400,1900 Lake Park Drive,678 384 7281,Biotechnology,Suite 380
t-2,GOVX,10737649.0,6327700,,,-570648,,-570648,435013,-1298,-436311,-436311,,-134427,,,,0,415458,851769,416756,-134337,,-570648,-570648,55203149.0,942153.0,10737649.0,11755897.0,3559.0,,-44469059.0,11010.0,11580594.0,923647.0,182584.0,10093.0,11734794.0,18506.0,161478.0,141154.0,87954.0,-2988.0,11155508.0,151609.0,11158496.0,10869912.0,-283126.0,-4050.0,46009.0,6000.0,-2470.0,-2470.0,10811147.0,en-US,US,EQUITY,True,Delayed Quote,5.64,1630526402,-0.4500003,6.2215,6.26,5.545,1016838,0.6024275,0.11958686,35688228,-3.6623378,1.7311234,15,America/New_York,EDT,-14400000,False,False,USD,2,"GeoVax Labs, Inc.",NCM,-1.26,-4.4761906,3.258,4.635857,1.0041428,0.21660347,5.0375724,0,finmb_12056751,NasdaqCM,"GeoVax Labs, Inc.",USD,2564462,1601357,3.08,1.203125,2.56 - 8.71,-3.0700002,-0.35246843,2.56,8.71,1600992000,1620331200,1620331200,1620331200,-1.477,-1.54,PREPRE,1.773048,1630540756,5.74,0.099999905,-7.389167,5.545 - 6.26,6.09,0.0,0.0,13,9,us_market,1.78,,,8.71,2.56,4.64,5.04,2.56M,1.6M,6.33M,,6.07M,8.31%,6.27%,181.61k,0.65,3.01%,2.87%,251.5k,,,,,,0.00%,"Sep 24, 2020",,1:20,"Sep 24, 2020","Dec 30, 2020","Mar 30, 2021",0.00%,-310.78%,-21.56%,-41.79%,1.22M,0.46,-84.60%,-620.8k,-3.76M,-3.93M,-1.48,,20.84M,3.3,195k,0.94,46.38,3.26,-4.01M,-4.25M,Value,30080,Healthcare,7,"GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against coronavirus (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; the HIV Vaccines Trial Network; Centers for Disease Control and Prevention; U.S. Department of Defense; U.S. Army Research Institute of Infectious Disease; U.S. Naval Research Laboratory; Emory University; University of Pittsburgh; Georgia State University Research Foundation; University of Texas Medical Branch; the Institute of Human Virology at the University of Maryland; the Scripps Research Institute; the Burnet Institute; American Gene Technologies International, Inc.; Viamune, Inc.; Geneva Foundation; the University of California; and Leidos, Inc. GeoVax Labs, Inc. was incorporated in 2001 and is based in Smyrna, Georgia.",Smyrna,678 384 7220,GA,1609372800,United States,http://www.geovax.com,86400,1900 Lake Park Drive,678 384 7281,Biotechnology,Suite 380
t-3,GOVX,-2225716.0,6327700,,,-455204,,-455204,427292,-20819,-448111,-448111,,-7153,,,,0,440602,888713,461421,-7093,,-455204,-455204,41658861.0,2807564.0,-2225716.0,957943.0,13834.0,,-43898411.0,11010.0,710682.0,2785865.0,182379.0,8618.0,938315.0,21699.0,91416.0,187163.0,-490479.0,1055748.0,1055748.0,27425.0,11158496.0,488875.0,-566873.0,6039.0,333346.0,12000.0,-2470.0,-2470.0,-1847550.0,en-US,US,EQUITY,True,Delayed Quote,5.64,1630526402,-0.4500003,6.2215,6.26,5.545,1016838,0.6024275,0.11958686,35688228,-3.6623378,1.7311234,15,America/New_York,EDT,-14400000,False,False,USD,2,"GeoVax Labs, Inc.",NCM,-1.26,-4.4761906,3.258,4.635857,1.0041428,0.21660347,5.0375724,0,finmb_12056751,NasdaqCM,"GeoVax Labs, Inc.",USD,2564462,1601357,3.08,1.203125,2.56 - 8.71,-3.0700002,-0.35246843,2.56,8.71,1600992000,1620331200,1620331200,1620331200,-1.477,-1.54,PREPRE,1.773048,1630540756,5.74,0.099999905,-7.389167,5.545 - 6.26,6.09,0.0,0.0,13,9,us_market,1.78,,,8.71,2.56,4.64,5.04,2.56M,1.6M,6.33M,,6.07M,8.31%,6.27%,181.61k,0.65,3.01%,2.87%,251.5k,,,,,,0.00%,"Sep 24, 2020",,1:20,"Sep 24, 2020","Dec 30, 2020","Mar 30, 2021",0.00%,-310.78%,-21.56%,-41.79%,1.22M,0.46,-84.60%,-620.8k,-3.76M,-3.93M,-1.48,,20.84M,3.3,195k,0.94,46.38,3.26,-4.01M,-4.25M,Value,30080,Healthcare,7,"GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against coronavirus (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; the HIV Vaccines Trial Network; Centers for Disease Control and Prevention; U.S. Department of Defense; U.S. Army Research Institute of Infectious Disease; U.S. Naval Research Laboratory; Emory University; University of Pittsburgh; Georgia State University Research Foundation; University of Texas Medical Branch; the Institute of Human Virology at the University of Maryland; the Scripps Research Institute; the Burnet Institute; American Gene Technologies International, Inc.; Viamune, Inc.; Geneva Foundation; the University of California; and Leidos, Inc. GeoVax Labs, Inc. was incorporated in 2001 and is based in Smyrna, Georgia.",Smyrna,678 384 7220,GA,1609372800,United States,http://www.geovax.com,86400,1900 Lake Park Drive,678 384 7281,Biotechnology,Suite 380
